Dong et al., 2019 - Google Patents
LncRNA PU. 1 AS regulates arsenic-induced lipid metabolism through EZH2/Sirt6/SREBP-1c pathwayDong et al., 2019
- Document ID
- 1317499850943519879
- Author
- Dong Z
- Li C
- Yin C
- Xu M
- Liu S
- Gao M
- Publication year
- Publication venue
- Journal of Environmental Sciences
External Links
Snippet
Arsenic (As) is an omnipresent metalloid toxicant, which has elicited serious environmental pollution and health risky problems. Previous studies have uncovered that the As exposure could also cause markedly reduction of serum triglycerides in mice. However, the regulation …
- 101710045142 SIRT6 0 title abstract description 41
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1 | |
Choi et al. | Glutamate signaling in hepatic stellate cells drives alcoholic steatosis | |
Dong et al. | LncRNA PU. 1 AS regulates arsenic-induced lipid metabolism through EZH2/Sirt6/SREBP-1c pathway | |
Scoles et al. | Antisense oligonucleotide therapy for spinocerebellar ataxia type 2 | |
Lin et al. | Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease | |
Jung et al. | Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK–SERCA2b pathway | |
Niture et al. | Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis | |
Saha et al. | Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | |
Ye et al. | Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice | |
Zhang et al. | Hepatic HuR modulates lipid homeostasis in response to high-fat diet | |
Chu et al. | MiR-181a regulates lipid metabolism via IDH1 | |
Yuan et al. | α-Ketoglutaric acid ameliorates hyperglycemia in diabetes by inhibiting hepatic gluconeogenesis via serpina1e signaling | |
Valsecchi et al. | NCX1 is a novel target gene for hypoxia-inducible factor-1 in ischemic brain preconditioning | |
Li et al. | TMCO1-mediated Ca2+ leak underlies osteoblast functions via CaMKII signaling | |
Drareni et al. | GPS2 deficiency triggers maladaptive white adipose tissue expansion in obesity via HIF1A activation | |
Martin et al. | Mitogen-and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter | |
Zheng et al. | Mitochondrion-processed TERC regulates senescence without affecting telomerase activities | |
Wei et al. | JAZF1 ameliorates age and diet-associated hepatic steatosis through SREBP-1c-dependent mechanism | |
Chu et al. | Liver Med23 ablation improves glucose and lipid metabolism through modulating FOXO1 activity | |
Xing et al. | Advanced Glycation End Products Induce Atherosclerosis via RAGE/TLR4 Signaling Mediated‐M1 Macrophage Polarization‐Dependent Vascular Smooth Muscle Cell Phenotypic Conversion | |
Li et al. | MiR-221-3p targets Hif-1α to inhibit angiogenesis in heart failure | |
Chen et al. | TXNIP regulates myocardial fatty acid oxidation via miR-33a signaling | |
Wang et al. | circ-CBFB upregulates p66Shc to perturb mitochondrial dynamics in APAP-induced liver injury | |
An et al. | TRIM59 expression is regulated by Sp1 and Nrf1 in LPS-activated macrophages through JNK signaling pathway | |
Wang et al. | Mitoferrin 2 deficiency prevents mitochondrial iron overload-induced endothelial injury and alleviates atherosclerosis |